Global risk assessment for lipid therapy to prevent coronary heart disease

Caitlin M. Nass, Stephen D. Wiviott, Jerilyn K. Allen, Wendy S Post, Roger S Blumenthal

Research output: Contribution to journalArticle

Abstract

Randomized clinical trials have established that lipidlowering pharmacologic therapy can substantially reduce morbidity and mortality in patients with known coronary artery disease (CAD). Researchers are now working to define the role of lipid-lowering agents in the primary prevention of CAD to extend their benefit to patients at increased risk for future coronary events. The risk assessment models presently used for secondary prevention are not sufficient to identify high-risk, asymptomatic patients. Building on the accumulated data about the physiologic mechanisms and metabolic factors that contribute to CAD, novel serum markers and diagnostic tests are being critically studied to gauge their utility for the assessment of high-risk patients and occult vascular disease. New risk prediction models that combine traditional risk factors for CAD with the prudent use of new screening methods will allow clinicians to target proven risk reduction therapies at high-risk patients before they experience a cardiac event.

Original languageEnglish (US)
Pages (from-to)424-432
Number of pages9
JournalCurrent Cardiology Reports
Volume2
Issue number5
DOIs
StatePublished - 2000

Fingerprint

Coronary Disease
Coronary Artery Disease
Lipids
Therapeutics
Risk Reduction Behavior
Primary Prevention
Secondary Prevention
Vascular Diseases
Routine Diagnostic Tests
Randomized Controlled Trials
Biomarkers
Research Personnel
Morbidity
Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Global risk assessment for lipid therapy to prevent coronary heart disease. / Nass, Caitlin M.; Wiviott, Stephen D.; Allen, Jerilyn K.; Post, Wendy S; Blumenthal, Roger S.

In: Current Cardiology Reports, Vol. 2, No. 5, 2000, p. 424-432.

Research output: Contribution to journalArticle

@article{d076382da5b745588ac4d522d547b9d9,
title = "Global risk assessment for lipid therapy to prevent coronary heart disease",
abstract = "Randomized clinical trials have established that lipidlowering pharmacologic therapy can substantially reduce morbidity and mortality in patients with known coronary artery disease (CAD). Researchers are now working to define the role of lipid-lowering agents in the primary prevention of CAD to extend their benefit to patients at increased risk for future coronary events. The risk assessment models presently used for secondary prevention are not sufficient to identify high-risk, asymptomatic patients. Building on the accumulated data about the physiologic mechanisms and metabolic factors that contribute to CAD, novel serum markers and diagnostic tests are being critically studied to gauge their utility for the assessment of high-risk patients and occult vascular disease. New risk prediction models that combine traditional risk factors for CAD with the prudent use of new screening methods will allow clinicians to target proven risk reduction therapies at high-risk patients before they experience a cardiac event.",
author = "Nass, {Caitlin M.} and Wiviott, {Stephen D.} and Allen, {Jerilyn K.} and Post, {Wendy S} and Blumenthal, {Roger S}",
year = "2000",
doi = "10.1007/s11886-000-0056-8",
language = "English (US)",
volume = "2",
pages = "424--432",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "5",

}

TY - JOUR

T1 - Global risk assessment for lipid therapy to prevent coronary heart disease

AU - Nass, Caitlin M.

AU - Wiviott, Stephen D.

AU - Allen, Jerilyn K.

AU - Post, Wendy S

AU - Blumenthal, Roger S

PY - 2000

Y1 - 2000

N2 - Randomized clinical trials have established that lipidlowering pharmacologic therapy can substantially reduce morbidity and mortality in patients with known coronary artery disease (CAD). Researchers are now working to define the role of lipid-lowering agents in the primary prevention of CAD to extend their benefit to patients at increased risk for future coronary events. The risk assessment models presently used for secondary prevention are not sufficient to identify high-risk, asymptomatic patients. Building on the accumulated data about the physiologic mechanisms and metabolic factors that contribute to CAD, novel serum markers and diagnostic tests are being critically studied to gauge their utility for the assessment of high-risk patients and occult vascular disease. New risk prediction models that combine traditional risk factors for CAD with the prudent use of new screening methods will allow clinicians to target proven risk reduction therapies at high-risk patients before they experience a cardiac event.

AB - Randomized clinical trials have established that lipidlowering pharmacologic therapy can substantially reduce morbidity and mortality in patients with known coronary artery disease (CAD). Researchers are now working to define the role of lipid-lowering agents in the primary prevention of CAD to extend their benefit to patients at increased risk for future coronary events. The risk assessment models presently used for secondary prevention are not sufficient to identify high-risk, asymptomatic patients. Building on the accumulated data about the physiologic mechanisms and metabolic factors that contribute to CAD, novel serum markers and diagnostic tests are being critically studied to gauge their utility for the assessment of high-risk patients and occult vascular disease. New risk prediction models that combine traditional risk factors for CAD with the prudent use of new screening methods will allow clinicians to target proven risk reduction therapies at high-risk patients before they experience a cardiac event.

UR - http://www.scopus.com/inward/record.url?scp=0034265997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034265997&partnerID=8YFLogxK

U2 - 10.1007/s11886-000-0056-8

DO - 10.1007/s11886-000-0056-8

M3 - Article

C2 - 10980910

AN - SCOPUS:0034265997

VL - 2

SP - 424

EP - 432

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 5

ER -